Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a key co‑factor in DNA, RNA and protein synthesis. By depleting tetrahydrofolate, the drug hampers the growth of rapidly dividing cells and suppresses immune activity, providing both antineoplastic and anti‑inflammatory effects.

The prescribed dose of Methotrexate Accord is individualized by the treating physician based on the specific indication, disease severity, patient weight, renal and hepatic function, and any concurrent therapies. Dosage regimens can vary widely, so the prescriber sets the exact amount and schedule for each patient.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Methotrexate Accord. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule folate antagonist that can be administered via injection and is generally less expensive. It has a well‑established efficacy profile for rheumatoid arthritis and certain cancers, but its safety monitoring requirements are more intensive than some newer biologics.

Methotrexate Accord should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided on the label.

The medication is supplied as a sterile injectable solution and can be given by intra‑arterial, intramuscular or intravenous injection, depending on the clinical indication and physician preference. Administration is performed by qualified healthcare professionals in a controlled setting.

Serious adverse events include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute renal failure and serious infections. Patients should be monitored regularly for liver enzymes, blood counts and renal function, and any new respiratory symptoms or signs of infection should be reported immediately.

Methotrexate Accord is contraindicated in pregnant women, nursing mothers, and patients with severe hepatic or renal impairment. It should also be avoided in individuals with known hypersensitivity to methotrexate or any of its excipients, and in patients receiving live vaccines without appropriate medical supervision.